Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Goodwill - Additional Information (Details)

v3.22.1
Goodwill - Additional Information (Details)
 12 Months Ended
Dec. 31, 2021
Unit
Segment
Plant
Country
Dec. 31, 2020
Disclosure Of Reconciliation Of Changes In Goodwill [Line Items]    
Number of segments | Segment 2  
Number of Cash-generating Unit | Unit 2  
Growth rate 1.00%  
Drug Containment Systems    
Disclosure Of Reconciliation Of Changes In Goodwill [Line Items]    
Number of countries where production plant located 5  
Percentage of average contraction of EBITDA at continuing value 44.61%  
Drug Containment Systems | Weighted Average Cost of Capital, Measurement Input    
Disclosure Of Reconciliation Of Changes In Goodwill [Line Items]    
Further sensitivity analysis resulted in identification of breakeven 17.07%  
In Vitro Diagnostic Consumables Drug Delivery Systems    
Disclosure Of Reconciliation Of Changes In Goodwill [Line Items]    
Number of countries where production plant located 2  
Number Of Plants | Plant 2  
Percentage of average contraction of EBITDA at continuing value 20.52%  
In Vitro Diagnostic Consumables Drug Delivery Systems | Weighted Average Cost of Capital, Measurement Input    
Disclosure Of Reconciliation Of Changes In Goodwill [Line Items]    
Further sensitivity analysis resulted in identification of breakeven 9.37%  
Engineering Systems    
Disclosure Of Reconciliation Of Changes In Goodwill [Line Items]    
Discount rate 6.20% 6.70%
Percentage of average contraction of EBITDA at continuing value 59.15%  
Engineering Systems | Weighted Average Cost of Capital, Measurement Input    
Disclosure Of Reconciliation Of Changes In Goodwill [Line Items]    
Further sensitivity analysis resulted in identification of breakeven 19.58%  
DCS and IVD & DDS    
Disclosure Of Reconciliation Of Changes In Goodwill [Line Items]    
Discount rate 6.30% 6.40%